Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio: Holistic value creation on the horizon

REG1VExtensive research2023-03-20 14:15
Inderes
Discuss
Download report (PDF)

Under the iCare brand, Revenio offers world-class tonometers, fundus imaging devices and perimeters. In recent years, the company has added software solutions to its offering, moving from being an equipment provider to a holistic eye diagnostics solution provider. The core business is growing very profitably, the market has sound growth drivers, and the company’s products have strong competitive advantages. At the same time, the company is creating future growth by developing new growth initiatives, of which Revenio has an excellent track record.

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures2023-03-18

202223e24e
Revenue97.0111.4129.6
growth-%23.1 %14.9 %16.3 %
EBIT (adj.)30.934.039.5
EBIT-% (adj.)31.8 %30.5 %30.5 %
EPS (adj.)0.720.820.96
Dividend0.300.350.46
Dividend %0.9 %3.4 %4.4 %
P/E (adj.)44.612.810.9
EV/EBITDA30.68.56.8

Forum discussions

in practice, this means they subscribed in the secondary subscription like any other sensible investor.
10/20/2026, 7:18 AM
by Critter
8
William Demant’s ownership has risen above 25%: Revenio Group Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus omistusosuuden...
10/20/2026, 7:01 AM
by NukkeNukuttaja
13
Yep, I ended up with the same. Got 7.65% of the shares subscribed with rights from the secondary subscription at a price of 6.19 EUR.
10/16/2026, 10:11 AM
by Opa
2
Looks like it’s correct: 42/552 = 7.6%. No need to worry about the rounding error.
10/16/2026, 10:11 AM
by Sergio
1
7.7% were allocated in the secondary subscription based on the amount subscribed for with subscription rights.
10/16/2026, 10:05 AM
by JuhaK
3
I exercised 1,242 subscription rights and received 42 new shares from the 1,000 shares I subscribed for in the secondary allocation. So, 4.2...
10/16/2026, 10:01 AM
by Sergio
1
Nordnet has refunded the money from the secondary subscription. From this, it can be deduced that by exercising 45 subscription rights (= 20...
10/16/2026, 9:29 AM
by roppakauppa
2